ELEV Logo

Elevation Oncology, Inc. (ELEV) 

NASDAQ$0.4815
Market Cap
$28.51M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
572 of 924
Rank in Industry
330 of 527

ELEV Insider Trading Activity

ELEV Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00
Sells
$00

Related Transactions

No records found

About Elevation Oncology, Inc.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Insider Activity of Elevation Oncology, Inc.

Over the last 12 months, insiders at Elevation Oncology, Inc. have bought $0 and sold $0 worth of Elevation Oncology, Inc. stock.

On average, over the past 5 years, insiders at Elevation Oncology, Inc. have bought $26M and sold $2.9M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 187,500 shares for transaction amount of $3M was made by Aisling Capital IV, LP (10 percent owner) on 2021‑06‑29.

List of Insider Buy and Sell Transactions, Elevation Oncology, Inc.

2022-05-25SaleRoyston Aaron
702,737
3.1622%
$4.12$2.9M-69.80%
2021-06-29PurchaseAisling Capital IV, LP10 percent owner
187,500
22.5074%
$16.00$3M-56.00%
2021-06-29PurchasevenBio Global Strategic Fund III, L.P.10 percent owner
625,000
75.0247%
$16.00$10M-56.00%
2021-06-29PurchaseQiming U.S. Healthcare Fund II, L.P.10 percent owner
312,500
37.5123%
$16.00$5M-56.00%
2021-06-29PurchaseVertex Global HC Fund II Pte. Ltd.10 percent owner
250,000
30.0099%
$16.00$4M-56.00%
2021-06-29PurchaseCormorant Asset Management, LP
250,000
30.0099%
$16.00$4M-56.00%
Total: 6

Insider Historical Profitability

<0.0001%
Aisling Capital IV, LP10 percent owner
2834910
4.7874%
$1.37M10<0.0001%
venBio Global Strategic Fund III, L.P.10 percent owner
2608167
4.4045%
$1.26M10<0.0001%
Qiming U.S. Healthcare Fund II, L.P.10 percent owner
2370142
4.0025%
$1.14M10<0.0001%
Vertex Global HC Fund II Pte. Ltd.10 percent owner
2307642
3.897%
$1.11M10<0.0001%
Cormorant Asset Management, LP
2233168
3.7712%
$1.08M10<0.0001%

Historical Insider Profitability vs. Competitors

$14,315,062
61
-6.21%
$30.86M
$53,490,060
55
19.35%
$32.57M
$94,084,626
29
-21.08%
$27.92M
$1,295,471
17
21.79%
$24.68M
$17,594,514
16
-20.37%
$32.66M

ELEV Institutional Investors: Active Positions

Increased Positions39+58.21%2M+4.68%
Decreased Positions24-35.82%9M-18.78%
New Positions14New1MNew
Sold Out Positions11Sold Out4MSold Out
Total Postitions82+22.39%40M-14.09%

ELEV Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Frazier Life Sciences Management, L.P.$3,195.0010.16%5.99M00%2024-12-31
Tang Capital Management Llc$2,537.008.07%4.76M00%2024-12-31
Farallon Capital Management Llc$1,880.005.98%3.53M00%2024-12-31
Blackrock, Inc.$1,686.005.36%3.16M+258,009+8.88%2024-12-31
Bvf Inc/Il$1,581.005.03%2.97M00%2024-12-31
Aisling Capital Management Lp$1,511.004.81%2.83M00%2024-12-31
Vanguard Group Inc$1,391.004.42%2.61M-461,535-15.03%2024-12-31
Goldman Sachs Group Inc$880.002.8%1.65M-2M-58.59%2024-12-31
Renaissance Technologies Llc$855.002.72%1.6M-182,673-10.23%2024-12-31
Geode Capital Management, Llc$617.001.96%1.16M+47,487+4.28%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.